Preclinical characterization of FGF21 in rodents and primates has established its role in restoring metabolic homeostasis in obese or metabolically challenged animals, reducing body weight, liver and circulating triglycerides, fasting plasma insulin and glucose, and increasing energy expenditure (61)
Examples are type 2 diabetes, obesity, cardiovascular factors, alcohol use, smoking, and depression
Clinicians and other health professionals will be changing treatment algorithms to capitalize on these early benefits in the evolution of diabetes
Buying drugs outside the US can be risky Going outside of the US for medicine or care can be risky
Interesting concept suggesting combination of GLP-1 receptor agonists and centrally acting fixed combination of naltrexone and bupropion Mechanistically,m it may make sense due to different pathways that are trargeted Gut HormoneHedonic Brain Axis and eating behaviors may be specifically targeted by naltrexone and bupropion combination thereby complementing the effects of GLP-1-based therapies #obesity #weightreduction #glp1receptoragonists #semaglutide #tirzepatide #naltrexin #bupropion #hedonicbrainaxis Martin Haluzks Post : Very interesting review just published in Obesity Science and Practice by Alex Miras and Muzamil Hussain
Peters et al., 2022)